Study Flow Diagram




Figure 1

Change From Baseline FEV_1 by Blood Eosinophil Count

EOS		Week 24* (From Interim)				Week 24 (From Stage I)			
	Treatment Group	N	Change from Baseline (L)	Difference	*p*-value	N	Change from Baseline (L)	Difference	*p*-value
<300	Placebo	109	0.024			115	0.015		
	2mg	13	0.082	0.061	---	13	0.082	0.078	---
	20mg	10	-0.068	-0.071	---	11	-0.013	-0.003	---
	100mg	104	0.064	0.044	0.274	108	0.071	0.061	0.125
≥ 300	Placebo	62	0.107			64	0.102		
	2mg	49	0.234	0.156	0.061	52	0.243	0.163	0.042
	20mg	51	0.252	0.152	0.042	55	0.264	0.168	0.023
	100mg	83	0.194	0.093	0.182	86	0.195	0.100	0.137

*Note: The Week 24 results at interim and the Week 24 results at Stage I analyses are consistent.

Figure 2

Change From Baseline FEV_1 by Blood Eosinophil Count

EOS		Week 24* (From Interim)				Week 52 (From Stage I)			
	Treatment Group	N	Change from Baseline (L)	Difference	*p*-value	N	Change from Baseline (L)	Difference	*p*-value
<300	Placebo	109	0.024			97	0.027		
	2mg	13	0.082	0.061	---	10	0.174	0.155	---
	20mg	10	-0.068	-0.071	---	10	0.107	0.100	---
	100mg	104	0.064	0.044	0.274	91	0.040	0.015	0.743
≥ 300	Placebo	62	0.107			53	-0.01		
	2mg	49	0.234	0.156	0.061	41	0.161	0.166	0.079
	20mg	51	0.252	0.152	0.042	48	0.201	0.232	0.019
	100mg	83	0.194	0.093	0.182	68	0.185	0.195	0.010

*Note: The Week 24 results at interim and the Week 24 results at Stage I analyses are consistent.

Figure 3

Change From Baseline FEV_1 by Baseline ICS Status

ICS		Week 24* (From Interim)				Week 52 (From Stage I)			
	Treatment Group	N	Change from Baseline (L)	Difference	*p*-value	N	Change from Baseline (L)	Difference	*p*-value
Medium	Placebo	100	0.092			88	0.047		
	2mg	28	0.318	0.220	0.013	25	0.233	0.170	0.061
	20mg	33	0.179	0.092	0.222	28	0.121	0.099	0.309
	100mg	100	0.108	0.016	0.737	83	0.083	0.038	0.474
High	Placebo	71	0.001			62	-0.032		
	2mg	34	0.107	0.108	0.151	26	0.096	0.134	0.140
	20mg	28	0.223	0.207	0.012	30	0.244	0.259	0.003
	100mg	88	0.135	0.129	0.034	77	0.118	0.144	0.024

*Note: The Week 24 results at interim and the Week 24 results at Stage I analyses are consistent.

Figure 4

Change From Baseline FEV_1 by Blood Eosinophil Count and Baseline ICS Status

EOS and ICS Status		Week 24* (From Interim)				Week 52 (From Stage I)			
	Treatment Group	N	Change from Baseline (L)	Difference	*p*-value	N	Change from Baseline (L)	Difference	*p*-value
ICS=Medium EOS < 300	Placebo	65	0.047			57	0.040		
	2mg	7	0.007	-0.034	---	3	0.100	0.048	0.803
	20mg	4	0.120	0.078	---	3	0.320	0.281	0.139
	100mg	52	0.074	0.028	0.615	46	0.044	0.004	0.945
ICS=High EOS < 300	Placebo	44	-0.009			40	0.008		
	2mg	6	0.170	0.177	---	7	0.206	0.191	0.131
	20mg	6	-0.193	-0.177	---	7	0.016	0.014	0.918
	100mg	52	0.053	0.064	0.284	45	0.035	0.027	0.669

*Note: The Week 24 results at interim and the Week 24 results at Stage I analyses are consistent.

Figure 5

Change From Baseline FEV_1 by Blood Eosinophil Count and Baseline ICS Status

EOS and ICS Status		Week 24* (From Interim)				Week 52 (From Stage I)			
	Treatment Group	N	Change from Baseline (L)	Difference	*p*-value	N	Change from Baseline (L)	Difference	*p*-value
ICS=Medium EOS ≥ 300	Placebo	35	0.175			31	0.060		
	2mg	21	0.422	0.237	0.079	22	0.251	0.167	0.212
	20mg	29	0.187	0.030	0.783	25	0.097	0.084	0.583
	100mg	48	0.144	-0.028	0.732	37	0.132	0.072	0.436
ICS=High EOS ≥ 300	Placebo	27	0.019			22	-0.105		
	2mg	28	0.094	0.094	0.357	19	0.055	0.187	0.163
	20mg	22	0.337	0.293	0.004	23	0.314	0.369	0.004
	100mg	35	0.263	0.254	0.033	31	0.249	0.357	0.003

*Note: The Week 24 results at interim and the Week 24 results at Stage I analyses are consistent.

Figure 6

FEV_1 by Baseline Eosinophil Count – Week 24

EOS Counts Cutoff	Treatment Group	N	Change from Baseline FEV1 at W24 (L)	Difference From PBO (L)	*p*-value
≥150	Placebo**	121	0.078		
	2 mg	59	0.223	0.163	0.011
	20mg	58	0.213	0.137	0.022
	100mg**	146	0.139	0.063	0.164
<150	Placebo	50	-0.001		
	2 mg	3	-0.200		
	20mg	3	-0.063		
	100mg	41	0.061	0.064	0.315
≥200	Placebo	108	0.091		
	2 mg	58	.230	.161	0.015
	20mg	58	0.213	0.123	0.048
	100mg	131	0.144	0.052	0.287
<200	Placebo	63	-0.008		
	2 mg	4	-0.200		
	20mg	3	-0.063		
	100mg	56	0.07	0.080	0.127

Figure 7A

FEV_1 by Baseline Eosinophil Count – Week 24

EOS Counts Cutoff	Treatment Group	N	Change from Baseline FEV1 at W24 (L)	Difference From PBO (L)	*p*-value
≥300	Placebo**	62	0.107		
	2 mg	49	0.234	0.156	0.061
	20mg	51	0.252	0.152	0.042
	100mg**	83	0.194	0.093	0.182
<300	Placebo	109	0.024		
	2 mg	13	0.082		
	20mg	10	-0.068		0.521
	100mg	104	0.064	0.044	0.274
≥400	Placebo	42	0.115		
	2 mg	36	0.270	0.170	0.124
	20mg	40	0.326	0.206	0.030
	100mg	49	0.260	0.156	0.064
<400	Placebo	129	0.034		
	2 mg	26	0.109	0.077	0.256
	20mg	21	-0.042	-0.07	0.353
	100mg	138	0.073	0.039	0.325

Figure 7B

Time Course of Mean FEV_1 from Baseline to Week 24 in Patients with at Least 300 Eosinophils/µl




Figure 8

Time Course of Mean FEV_1 from Baseline to Week 24 in Patients Less than 300 Eosinophils/µl




Figure 9